Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...

Madrigal Pharmaceuticals (MDGL) announced on Friday an exclusive global license agreement with Pfizer (PFE) for ervogastat, ...

Now, it’s worth noting Stock Advisor’s total average return is 971 % — a market-crushing outperformance compared to 196% for ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

The FDA approved a new safety warning for Depo-Provera alerting patients to a possible risk for a type of brain tumor called meningioma.

At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...

Pfizer (NYSE:PFE) has received FDA accelerated approval for its drug Braftovi in combination with other therapies as a first-line treatment for metastatic colorectal cancer, or mCRC, with a BRAF gene ...

Pfizer is taking a more hands-on approach to AI in drug research, teaming up with startup Boltz to help its scientists make ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders.